US 12,221,488 B2
APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01
Cheng Zhang, Hangzhou (CN); Lei Sun, Hangzhou (CN); Rongzhu Wang, Hangzhou (CN); Chenjiang Yao, Hangzhou (CN); Xiaofeng Wang, Hangzhou (CN); Hua Zhang, Hangzhou (CN); and Shuqian Jing, Hangzhou (CN)
Appl. No. 17/251,663
Filed by GMAX BIOPHARM LLC, Hangzhou (CN)
PCT Filed Jun. 13, 2019, PCT No. PCT/CN2019/091090
§ 371(c)(1), (2) Date Dec. 11, 2020,
PCT Pub. No. WO2019/238093, PCT Pub. Date Dec. 19, 2019.
Claims priority of application No. 201810606914.0 (CN), filed on Jun. 13, 2018.
Prior Publication US 2021/0163614 A1, Jun. 3, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 14/47 (2006.01); C07K 14/72 (2006.01)
CPC C07K 16/2869 (2013.01) [C07K 14/4705 (2013.01); C07K 14/723 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)] 12 Claims
 
1. An antibody specifically binding to human apelin receptor (APJ), wherein the antibody comprises:
a. light chain CDR1 amino acid sequence: SEQ ID NO: 1; light chain CDR2 amino acid sequence: SEQ ID NO: 2; light chain CDR3 amino acid sequence: SEQ ID NO: 3; heavy chain CDR1 amino acid sequence: SEQ ID NO: 12; heavy chain CDR2 amino acid sequence: SEQ ID NO: 13; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 14;
b. light chain CDR1 amino acid sequence: SEQ ID NO: 4; light chain CDR2 amino acid sequence: SEQ ID NO: 5; light chain CDR3 amino acid sequence: SEQ ID NO: 6; heavy chain CDR1 amino acid sequence: SEQ ID NO: 15; heavy chain CDR2 amino acid sequence: SEQ ID NO: 16; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 17;
c. light chain CDR1 amino acid sequence: SEQ ID NO: 7; light chain CDR2 amino acid sequence: SEQ ID NO: 8; light chain CDR3 amino acid sequence: SEQ ID NO: 9; heavy chain CDR1 amino acid sequence: SEQ ID NO: 18; heavy chain CDR2 amino acid sequence: SEQ ID NO: 19; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 20; or
d. light chain CDR1 amino acid sequence: SEQ ID NO: 10; light chain CDR2 amino acid sequence: SEQ ID NO: 5; light chain CDR3 amino acid sequence: SEQ ID NO: 11; heavy chain CDR1 amino acid sequence: SEQ ID NO: 18; heavy chain CDR2 amino acid sequence: SEQ ID NO: 21; and heavy chain CDR3 amino acid sequence: SEQ ID NO: 22.